---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-064791"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:40:17.350823+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ACAD's Phase 3 ADVANCE-2 trial of pimavanserin misses primary endpoint in negative symptoms of schizophrenia

## Summary
- Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.
- Safety and tolerability consistent with prior trials, showing low adverse event rate.
- No financial or regulatory guidance provided in this 8-K; further analysis may follow.

## SEC filing metadata
- accession: 0001193125-24-064791
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/0001193125-24-064791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/d786050d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-064791
- JSON: https://secwatch.observer/filing/0001193125-24-064791.json
- Plain text: https://secwatch.observer/filing/0001193125-24-064791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.